Search Results

greater number of patients will be unable to complete the intended course of adjuvant therapy for similar reasons. 7 , 8 The administration of chemotherapy with or without radiation therapy (RT) before surgical resection is an alternative strategy that

. Goss PE Ingle JN Pritchard KI . Extending aromatase-inhibitor adjuvant therapy to 10 years . N Engl J Med 2016 ; 375 : 209 – 219 . 4. Goss PE Ingle JN Martino S . Impact of premenopausal status at breast cancer diagnosis in women entered

personalize systemic adjuvant therapy choices,” Dr. Ward said. “The available assays have strong prognostic capability, and more data on this are coming.” Among the available assays are the 21-gene panel (Oncotype Dx), the 70-gene panel (MammaPrint), the 50

just predicting a recurrence. It’s actually detecting residual disease. It appears to be the most useful prognostic assay, but there are unanswered questions, and we still don’t know if it can guide adjuvant therapy,” she said. Although ctDNA assays can

the completion of adjuvant therapy. Thus, physical activity has been shown to have several benefits for patients with breast cancer both during and after adjuvant therapy. No clear consensus exists on the “best” type of physical activity, but

in endometrial carcinoma: overview of randomised trials . Clin Oncol (R Coll Radiol) 2008 ; 20 : 463 – 469 . 56 Fleming G . Adjuvant therapy for high-risk adenocarcinoma of the uterus . ASCO Educational Book 2008 : 230 – 233

adjuvant therapy data (n=3). A total of 29 patients received postoperative RT and were excluded from the analysis of factors associated with omission of preoperative RT. The minimum follow-up time was 120 days for all patients. Variables Analyzed

-free and overall survival. 7 The effectiveness of aromatase inhibitors in the treatment of metastatic breast cancer led to a number of trials incorporating them into the adjuvant therapy of postmenopausal women with early-stage hormone receptor

34%, 1 , 3 a favorable outcome that has been attributed to the combination of increased screening mammography and improved adjuvant therapy. 4 However, despite the steady increase in DCIS detection and treatment in the 1990s, the subsequent

considered at high risk for recurrence after adjuvant therapy, interferon-alfa appears to confer a small benefit. The value of high-dose interferon was first established in 1996 by Kirkwood et al. 5 for patients with T4 lesions or evidence of regional